We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

79 hedge funds and large institutions have $1.03B invested in Adaptimmune Therapeutics in 2020 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $2.02M | Put options by funds: $1.04M

21% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 19

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

3% more funds holding

Funds holding: 77 → 79 (+2)

0.2% less ownership

Funds ownership: 14.19% → 13.99% (-0.2%)

20% less capital invested

Capital invested by funds: $1.28B → $1.03B (-$254M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
79
Holders Change
+2
Holders Change %
+2.6%
% of All Funds
1.59%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
23
Increased
23
Reduced
19
Closed
20
Calls
$2.02M
Puts
$1.04M
Net Calls
+$985K
Net Calls Change
+$6.21M

Top Buyers

Rank Fund Capital Flow
1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$15.7M
2
Citadel Advisors
Citadel Advisors
Florida
+$14.9M
3
Victory Capital Management
Victory Capital Management
Texas
+$8.81M
4
ACA
Avoro Capital Advisors
New York
+$8.75M
5
PHS
PFM Health Sciences
California
+$7.43M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$15.1M
2
ACP
Acuta Capital Partners
California
-$11.7M
3
Millennium Management
Millennium Management
New York
-$9.48M
4
VA
VR Adviser
New York
-$7.83M
5
Marshall Wace
Marshall Wace
United Kingdom
-$3.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
26
California Public Employees Retirement System
California
$2.23M +$381K +43,486 +18%
State Street
27
State Street
Massachusetts
$1.64M +$294K +33,551 +19%
AA
28
ALPS Advisors
Colorado
$1.57M -$72.4K -8,278 -4%
GAMA
29
Graticule Asia Macro Advisors
New York
$1.46M +$1.61M +183,480 New
Stifel Financial
30
Stifel Financial
Missouri
$1.33M +$1.32M +151,031 +979%
MWNA
31
Marshall Wace North America
New York
$1.23M -$2.48M -283,232 -65%
VIA
32
Vident Investment Advisory
Georgia
$1.06M -$63.8K -7,289 -5%
UBS Group
33
UBS Group
Switzerland
$1M +$1.1M +125,263 +178,947%
WM
34
WS Management
Florida
$970K – – –
Geode Capital Management
35
Geode Capital Management
Massachusetts
$883K +$435K +49,703 +82%
SFI
36
Susquehanna Fundamental Investments
Pennsylvania
$825K +$342K +39,135 +61%
GCP
37
GSA Capital Partners
United Kingdom
$590K +$647K +73,947 New
Man Group
38
Man Group
United Kingdom
$588K +$319K +36,498 +98%
Squarepoint
39
Squarepoint
New York
$505K +$554K +63,285 New
AC
40
Athanor Capital
New York
$501K -$258K -29,526 -32%
HS
41
HighVista Strategies
Massachusetts
$443K +$486K +55,479 New
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$345K -$19K -2,169 -5%
Envestnet Asset Management
43
Envestnet Asset Management
Illinois
$336K +$369K +42,115 New
OC
44
Oppenheimer & Co
New York
$294K +$322K +36,837 New
VFA
45
Voya Financial Advisors
Connecticut
$290K +$331K +37,820 New
AG
46
Aperio Group
California
$271K +$92.5K +10,575 +45%
VAS
47
Vestmark Advisory Solutions
Massachusetts
$252K +$276K +31,536 New
VEA
48
Virtus ETF Advisers
New York
$247K -$37K -4,232 -12%
TC
49
TownSquare Capital
Utah
$247K +$260K +29,739 New
ECM
50
ExodusPoint Capital Management
New York
$244K +$268K +30,607 New
1
2
3 4

ADAP Hedge Fund Activity: Q3 2020 in Review

79 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2020, worth a combined $1.03B — down 20% from $1.28B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ADAP positions and 20 closed out — a net gain of 3 holders — while 23 added to existing stakes and 19 trimmed.

The largest buyer was Baillie Gifford & Co, adding an estimated $15.7M. The largest seller was RA Capital Management, cutting an estimated $15.1M.

  • 79 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2020, up from 77 in Q2 2020.
  • Funds reported $1.03B of Adaptimmune Therapeutics stock for Q3 2020, down 20% quarter-over-quarter.
  • 23 funds opened new Adaptimmune Therapeutics positions in Q3 2020 and 20 closed out, a net change of +3 holders.
  • The largest Adaptimmune Therapeutics buyer in Q3 2020 was Baillie Gifford & Co, an estimated $15.7M added.
  • The largest Adaptimmune Therapeutics seller in Q3 2020 was RA Capital Management, an estimated $15.1M sold.

Based on aggregated 13F filings for Q3 2020.